PACIRA BIOSCIENCES, INC. Defined Contribution Plan, Increase (Decrease), Cost
PACIRA BIOSCIENCES, INC. (PCRX) reported Defined Contribution Plan, Increase (Decrease), Cost of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanIncreaseDecreaseCost · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. defined contribution plan, increase (decrease), cost for fiscal 2025 was $100.00K.
- PACIRA BIOSCIENCES, INC. defined contribution plan, increase (decrease), cost for fiscal 2024 was -$100.00K, a 133.33% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. defined contribution plan, increase (decrease), cost for fiscal 2023 was $300.00K.
| Period end | Defined Contribution Plan, Increase (Decrease), Cost 12 month |
|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | -$100.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $300.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |